Close

UBS Maintains a 'Buy' on Celgene (CELG); Tough Scenario, but NPV Still Supportive

June 22, 2012 11:03 AM EDT
Get Alerts CELG Hot Sheet
Price: $108.24 --0%

Rating Summary:
    7 Buy, 27 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
UBS maintains a 'Buy' on Celgene (NASDAQ: CELG) price target of $78.00 (from $85.00).

Analyst, Matthew Roden, said, "We are lowering Revlimid numbers as we remove EU maintenance from our model, as we are skeptical of near-mid term approval in this setting. However, we see clearly favorable riskreward in CELG shares overall at these levels given (1) very low expectations for near term apremilast data, (2) lower risk to accelerated approval of pomalidomide, and upside to pom fore casts (UBSe 2015 $712m vs. cons $360m), and (3) upside to Revlimid front-line market share through use of CRd (carfilzomib-Revlimid-dex) after impressive ASCO complete response data."

For UBS, the current multiple implies limited downside from here, and notes the company's growth profile. CELG is now trading at 10.8c UBS's new 2013 PES ($5.52 from $5.58), despite its 23% 4-yr EPS CAGR, which UBS analyst finds attractive relative to biotech comps and the pharma group (13x and 12x)

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $59.45 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

UBS